Clinical Trials Directory

Trials / Completed

CompletedNCT00403351

Alternative Risk Markers in Coronary Artery Disease (ARMCAD)

Correlation of Multiple Risk Factors With Presence and Severity of Coronary Artery Disease.

Status
Completed
Phase
Study type
Observational
Enrollment
665 (actual)
Sponsor
Monash University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Estimating the risk of future cardiovascular events such as death, stroke and myocardial infarction using traditional risk factors (such as age, gender, smoking, diabetes, hyperlipidaemia and hypertension) is well accepted in patients with and without existing cardiovascular disease. These estimates are based on a number of robust observational studies, including the original Framingham study. While these methods apply reasonably well on a population level their application to the individual patients is not always straightforward. In addition, risk charts, such as those published by the Joint British Societies and American Heart Association, may underestimate risk in certain groups, notably diabetics and patients of Indo-Asian background, whilst overestimating risk in others (by as much as 50% in some studies).

Detailed description

A number of variables including clinical, biochemical, and enzymatic have been evaluated to see if they add to conventional "risk-reduction" models such as Framingham and if so, to understand if they may be used in routine clinical practice. The aim of this study is to assess several known and a few novel risk-factors (heart rate variability, pulse wave analysis, high-sensitivity CRP and BNP) prior to planned elective coronary angiography (cross-sectional analysis) and in a prospective cohort of high and low-risk patients.

Conditions

Timeline

Start date
2006-10-01
Primary completion
2008-06-01
Completion
2016-05-01
First posted
2006-11-23
Last updated
2020-09-02

Locations

4 sites across 1 country: Australia

Source: ClinicalTrials.gov record NCT00403351. Inclusion in this directory is not an endorsement.